Why the study?
The study aimed to investigate the outcomes of percutaneous coronary intervention in patients with rheumatoid arthritis.
Does the presence of rheumatoid arthritis increase the risk of adverse outcomes in patients undergoing percutaneous coronary intervention?
Does the presence of rheumatoid arthritis increase the risk of adverse outcomes in patients undergoing percutaneous coronary intervention?
Patients with rheumatoid arthritis undergoing PCI have a significantly higher risk of major adverse cardiovascular events compared to non-RA patients, suggesting a need for tailored post-procedural care.
RA patients show higher post-PCI MACE risk; supports closer monitoring but leaves practice change open pending RCTs.
AIM: The present study aims to investigate the outcomes of Percutaneous coronary intervention (PCI) in patients with Rheumatoid arthritis (RA). METHODS: A systemic search was conducted from electronic databases (PubMed/Medline, Cochrane Library, and Google Scholar) from inception to 15th September 2023. All statistical analyses were conducted using Review Manager 5.4.1. Studies meeting inclusion criteria were selected. A random-effect model was used when heterogeneity was seen to pool the studies, and the result was reported in the odds ratio (OR) and the corresponding 95 % confidence interval (CI). RESULTS: Eight observational studies were selected to conduct the analysis. A statistically significant increase in major adverse cardiovascular event (MACE) was seen in RA patients after undergoing PCI as compared to the control group (OR = 1.18 (1.16, 1.21); p < 0.00001; I2 = 0 %). There was no significant difference found in the long-term revascularization outcome between the RA and non-RA patients (OR = 1.18 (0.81, 1.71); p = 0.39; I2 = 93 %). Survival rates of all-cause mortality in the long-term outcome were statistically insignificant among the two groups (OR = 1.21 (0.84, 1.74); p = 0.31; I2 = 99 %). CONCLUSION: Percutaneous coronary intervention is an important intervention to reduce morbidity and mortality but special precautions and attention should be made when it comes to patients with RA. Different precautions such as close monitoring for medication interaction, and tailored post-procedural care are essential in reducing morbidity and mortality.
No takes yet. Share an insight, caveat, or question.
Piplani et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: